Evaluation of the SIOPEN semi-quantitative scoring system in planar simpatico-adrenal MIBG scintigraphy in children with neuroblastoma.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Neoplasma (Bratislava)

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.4149/neo_2015_053PMID 25866225
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Evaluation of bone marrow as a metastatic site of human neuroblastoma

  2015cited by this paper
• Combined Scintigraphy and Tumor Marker Analysis Predicts Unfavorable Histopathology of Neuroblastic Tumors with High Accuracy

  2015cited by this paper
• Urinary homovanillic and vanillylmandelic acid in the diagnosis of neuroblastoma: report from the Italian Cooperative Group for Neuroblastoma.

  2014cited by this paper
• Case Report of PET/CT Imaging of a Patient With Neuroblastoma Using 18F-FPBG

  2014cited by this paper
• MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis

  2014cited by this paper
• Presence of Differentiating Neuroblasts in Bone Marrow is a Favorable Prognostic Factor for Bone Marrow Metastatic Neuroblastoma at Diagnosis

  2013cited by this paper
• Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study.

  2013cited by this paper
• Synthesis and evaluation of 18F-labeled benzylguanidine analogs for targeting the human norepinephrine transporter

  2013cited by this paper
• Semiquantitative mIBG Scoring as a Prognostic Indicator in Patients with Stage 4 Neuroblastoma: A Report from the Children’s Oncology Group

  2013cited by this paper
• Clinical presentation

  2013cited by this paper
• Neuroblastoma: The impact of biology and cooperation leading to personalized treatments

  2012influential reference
• Prognostic value of ferritin, neuron-specific enolase, lactate dehydrogenase, and urinary and plasmatic catecholamine metabolites in children with neuroblastoma

  2012cited by this paper
• Incidence, survival, and prevalence of neuroendocrine tumors versus neuroblastoma in children and young adults: Nine standard SEER registries, 1975–2006

  2011cited by this paper
• Urine catecholamines in paediatrics

  2011cited by this paper
• Comparison of 123I‐metaiodobenzylguanidine (MIBG) and 131I‐MIBG semi‐quantitative scores in predicting survival in patients with stage 4 neuroblastoma: A report from the Children's Oncology Group

  2011cited by this paper
• Radioiodinated metaiodobenzylguanidine (MIBG): radiochemistry, biology, and pharmacology.

  2011cited by this paper
• Pediatrics: diagnosis of neuroblastoma.

  2011cited by this paper
• Epidemiology of childhood cancer.

  2010cited by this paper
• THE PROGNOSTIC SIGNIFICANCE OF VANILLYLMANDELLIC ACID IN NEUROBLASTOMA

  2010cited by this paper
• Criteria for evaluation of disease extent by 123I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force

  2010cited by this paper
• Neuroblastoma: biology, prognosis, and treatment.

  2010cited by this paper
• Unchanged incidence and increased survival in children with neuroblastoma in Denmark 1981–2000: a population-based study

  2009cited by this paper
• The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report.

  2009cited by this paper
• Unchanged incidence and increased survival in children with neuroblastoma in Denmark 1981–2000: a population-based study

  2009cited by this paper
• Catecholaminergic systems in stress: structural and molecular genetic approaches.

  2009cited by this paper
• Molecular imaging in neuroendocrine tumors: molecular uptake mechanisms and clinical results.

  2009cited by this paper
• Diagnostic and prognostic markers in infants with disseminated neuroblastoma: a retrospective analysis from the Italian Cooperative Group for Neuroblastoma.

  2008cited by this paper
• Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.

  2008cited by this paper
• Diagnostic and prognostic impact of urinary catecholamines in neuroblastoma patients

  2007cited by this paper
• Prognostic significance of biochemical heterogeneity of catecholaminergic clones in neuroblastoma.

  2006cited by this paper
• Prognostic value of the International Neuroblastoma Pathology Classification in Neuroblastoma (Schwannian stroma-poor) and comparison with other prognostic factors: a study of 182 cases from the Spanish Neuroblastoma Registry

  2006cited by this paper
• MYCN gene amplification is a powerful prognostic factor even in infantile neuroblastoma detected by mass screening

  2006cited by this paper
• Evaluation of semi‐quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma

  2006cited by this paper
• Neuroblastoma update

  2005cited by this paper
• Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group.

  2005cited by this paper
• Neuroblastoma: a disease requiring a multitude of imaging studies.

  2004cited by this paper
• MYCN-status in neuroblastoma: characteristics of tumours showing amplification, gain, and non-amplification.

  2004cited by this paper
• A Systematic Review of Molecular and Biological Tumor Markers in Neuroblastoma

  2004cited by this paper
• Catecholamine Metabolism: A Contemporary View with Implications for Physiology and Medicine

  2004cited by this paper
• Comparative values of catecholamines and metabolites for the diagnosis of neuroblastoma

  2003cited by this paper
• Guidelines for radioiodinated MIBG scintigraphy in children

  2003influential reference
• Tumour markers are poor predictors for relapse or progression in neuroblastoma.

  2003cited by this paper
• Evolving significance of prognostic markers associated with new treatment strategies in neuroblastoma.

  2003cited by this paper
• Functional scintigraphy of the adrenal gland.

  2002cited by this paper
• Morphologic features of neuroblastoma (Schwannian stroma‐poor tumors) in clinically favorable and unfavorable groups

  2002cited by this paper
• Molecular cytogenetics.

  2001cited by this paper
• Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors

  2001cited by this paper
• International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors

  2001cited by this paper
• Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group 'Survey' 1982-1992.

  2000cited by this paper
• Natural history and biology of stage A neuroblastoma: a Pediatric Oncology Group Study.

  2000cited by this paper
• Combined (111)In-pentetreotide scintigraphy and (123)I-mIBG scintigraphy in neuroblastoma provides prognostic information.

  2000cited by this paper
• Metaiodobenzylguanidine assessment of metastatic neuroblastoma: observer dependency and chemosensitivity evaluation. The SFOP Group.

  2000cited by this paper
• Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: results of the French Society of Pediatric Oncology

  2000cited by this paper
• Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study.

  2000cited by this paper
• Clinical impact and prognostic value of metaiodobenzylguanidine imaging in children with metastatic neuroblastoma.

  1999cited by this paper
• Epidemiology of childhood cancer.

  1999cited by this paper
• Incidence of neuroblastoma.

  1999cited by this paper
• The International Neuroblastoma Pathology Classification (the Shimada system)

  1999cited by this paper
• Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution

  1999cited by this paper
• Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival.

  1999cited by this paper
• [Iodine-123-MIBG scintigraphy in neuroblastoma; relationship between the intensity of uptake and tumor characteristics].

  1999cited by this paper
• Terminology and morphologic criteria of neuroblastic tumors

  1999cited by this paper
• Neuron-Specific Enolase Evaluation in Patients with Neuroblastoma

  1998cited by this paper
• Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience--a pediatric oncology group study.

  1998cited by this paper
• Activity of iodine-123 metaiodobenzylguanidine in childhood neuroblastoma: lack of relation to tumour differentiation in vivo

  1998cited by this paper
• Correlation between Morphologic and Nonmorphologic Prognostic Markers of Neuroblastoma

  1997cited by this paper
• PET hydroxyephedrine imaging of neuroblastoma.

  1996cited by this paper
• Neuroblastoma: A clinical challenge and biologic puzzle

  1995cited by this paper
• A new 123I-MIBG whole body scan scoring method--application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma.

  1995cited by this paper
• No-carrier-added meta-[123I]iodobenzylguanidine: synthesis and preliminary evaluation.

  1995cited by this paper
• Iodine-131-MIBG imaging to monitor chemotherapy response in advanced neuroblastoma: comparison with laboratory analysis.

  1994cited by this paper
• A comparison of iodine-123 meta-iodobenzylguanidine scintigraphy and single bone marrow aspiration biopsy in the diagnosis and follow-up of 26 children with neuroblastoma

  1993cited by this paper
• Screening for neuroblastoma.

  1993cited by this paper
• Kinetics of isotope exchange between [3-(iodophenyl)methyl]guanidine (mIBG) and [131I]-iodide

  1992cited by this paper
• A population-based study of neuroblastoma incidence, survival, and mortality in North America.

  1992cited by this paper
• Serum vanillylmandelic acid/homovanillic acid contributes to prognosis estimation in patients with localised but not with metastatic neuroblastoma.

  1992cited by this paper
• [Treatment of neuroblastoma].

  1991cited by this paper
• Serum neuron-specific enolase in children's cancer.

  1987influential reference
• Neuroblastoma: A Specific Sonographic Tissue Pattern

  1987cited by this paper
• Neuroblastoma: the role of MR imaging.

  1987cited by this paper
• Serum neuron‐specific enolase in children with neuroblastoma. Crelationship to stage and disease course

  1986influential reference
• Prognostic importance of serum ferritin in patients with Stages III and IV neuroblastoma: the Childrens Cancer Study Group experience.

  1985cited by this paper
• Nervous system-specific enolase in serum as a marker for neuroblastoma.

  1983influential reference
• Raised neuron-specific enolase in serum of children with metastatic neuroblastoma. A report from the Children's Cancer Study Group.

  1983influential reference
• High levels of immunoreactive nervous system-specific enolase in sera of patients with neuroblastoma.

  1982influential reference
• Serum ferritin as a guide to therapy in neuroblastoma.

  1980influential reference
• Onco-neural antigen: a new neural differentiation antigen expressed by neuroblastoma, oat cell carcinoma, Wilms' tumor, and sarcoma cells.

  1979cited by this paper

• Comparison of the detecting capability between 123I-mIBG and post-therapeutic 131I-mIBG scintigraphy for curie scoring in patients with neuroblastoma after chemotherapy

  2021cites this paper
• Pictorial review of the clinical applications of MIBG in neuroblastoma: current practices

  2020cites this paper
• Clinical Relevance of 18F-FDG PET/CT in the Postoperative Follow-up of Patients with History of Medullary Thyroid Cancer

  2020cites this paper
• Nuklearmedizinische Therapie von Nebennierentumoren

  2019cites this paper
• Norepinephrine Transporter as a Target for Imaging and Therapy

  2017cites this paper
• Neuroblastoma in children: Update on clinicopathologic and genetic prognostic factors

  2017cites this paper